Friday, 16 December 2022

SECTOR UPDATE

Automobile - China

Weekly: Passenger EV Sales Up 16.7% mom In The Second Week Of Dec 22

In the second week of Dec 22, daily average PV retail sales rebounded 6% yoy and 40% mom, while insurance registrations of passenger EVs grew 16.7% mom and 8.5% wow. Looking into 2023, we expect ICV sales to drop 13% and EV sales to grow 30%, implying a hike in EVs' market share from 25% in 2022 to 33% in 2023. Maintain UNDERWEIGHT. CATL, Fuyao Glass and Xusheng remain our top picks, and we add Desay into our list of top picks. Upgrade Li Auto from HOLD to BUY on valuation.

WHAT'S NEW

- CPCA: Daily average PV retail sales rebounded 6% yoy and 40% mom in the second week of Dec 22, beating estimates. According to China Passenger Car Association (CPCA), daily average passenger vehicle (PV) wholesale shipment in China declined 18% yoy but surged 22% mom during 5-11 Dec 22. The catalysts that will spur vehicle sales at the year-end include: a) easing COVID-19-containment measures, b) last-minute purchases right before the expiry of stimulus, and c) debuts of more models.
- Insurance registrations of passenger EVs in China grew 16.7% mom and 8.5% wow in the second week of Dec 22 (5-11 Dec 22). In the first two weeks of Dec 22 (28 Nov-11 Dec 22), insurance registrations (a proxy to retail sales volume) of passenger EVs in China grew 16.7% mom to 269,000 units. The rebound in insurance registrations in Dec 22 was due to easing COVID-19-containment measures and the rush to buy EVs before the expiry of EV purchase subsidies on 31 Dec 22.
- BYD's wholesale shipment exceeded the combined volume of retail sales and exports by 18% or 128,000 units in Aug-Nov 22, implying inventory build-up at dealers. Note that BYD's wholesale shipment of passenger EVs grew from 173,977 units in Aug 22 to 200,973 units/217,518 units/229,942 units in Sep/Oct/Nov 22. However, BYD"s insurance registrations only reached 156,417 units/166,882 units/160,214 units/176,189 units in Aug/Sep/Oct/Nov 22, and export volume grew from 5,092 units in Aug 22 to 7,736 units/9,529 units/12,318 units in Sep/Oct/Nov 22. BYD registered a combined wholesale shipment of 882,410 units from Aug 22 to Nov 22, and the combined volume of insurance registrations and exports only reached 694,377 units. This implies 128,033 units (the difference between 882,410 and 694,377) of inventories were accumulated at dealerships. We estimate that inventory-to-sales ratio of BYD increased from 1.0 month as of Jul 22 to 1.7 months currently.

UNDFRWFIGHT


(Maintained)

TOP PICKS

| Company | Ticker | Rec | Snare Price (Icy) | Price (lcy) |
|----------------|-----------|-----|-------------------------|----------------|
| CATL | 300750 CH | BUY | 423.80 | 640.00 |
| Desay SV | 002920 CH | BUY | 119.57 | 161.00 |
| Fuyao Glass | 3606 HK | BUY | 34.35 | 45.00 |
| Ningbo Xusheng | 603305 CH | BUY | 36.39 | 59.00 |


Source: UOB Kay Hian

WEEKLY STOCK PERFORMANCE



Source: Bloomberg

RELATIVE PERFORMANCE OF AUTO STOCKS



Source: Bloomberg

ANALYST(S)

Ken Lee +852 2236 676

+852 2236 6760 ken.lee@uobkayhian.com.hk

Jessie Guo

+86 21 5404 7225 ext. 810 jessieguo@uobkayhian.com

PEER COMPARISON

| Company | Ticker | Rec | Price @ | Target | Upside/ | Market | P | E | P | P/B | | Net |
|-------------------|-----------|------|-----------|--------|------------|----------------|-------|-------|-------|-------|--------|------------|
| , , | | | 15 Dec 22 | Price | (Downside) | Cap (US\$m) | 2022F | 2023F | 2022F | 2023F | ROE | Gearing |
| | | | (Icy) | (lcy) | to TP (%) | | (x) | (x) | (x) | (x) | (%) | (Cash) (%) |
| BYD | 1211 HK | BUY | 206.80 | 440.00 | 112.8 | 77,437 | 45.0 | 28.4 | 5.1 | 4.4 | 12.1 | (16.9) |
| Geely Automobile | 175 HK | HOLD | 12.00 | 13.00 | 8.3 | 15,464 | 20.5 | 14.1 | 1.5 | 1.4 | 7.6 | (38.1) |
| Great Wall Motors | 2333 HK | BUY | 10.44 | 13.00 | 24.5 | 12,327 | 10.1 | 9.1 | 1.2 | 1.1 | 13.1 | (25.0) |
| Guangzhou Auto | 2238 HK | BUY | 5.41 | 7.50 | 38.6 | 7,146 | 5.3 | 4.4 | 0.5 | 0.5 | 10.2 | (7.3) |
| Li Auto Inc | 2015 HK | BUY | 80.65 | 100.00 | 24.0 | 22,546 | Loss | Loss | 3.1 | 3.2 | (4.8) | (103.1) |
| XPeng Inc | 9868 HK | SELL | 40.15 | 28.00 | (30.3) | 9,865 | Loss | Loss | 1.9 | 2.8 | (23.0) | (88.1) |
| Weichai Power | 2338 HK | SELL | 10.86 | 8.50 | (21.7) | 12,190 | 8.6 | 7.1 | 1.2 | 1.1 | 4.7 | (69.8) |
| Fuyao Glass | 3606 HK | BUY | 34.35 | 45.00 | 31.0 | 11,531 | 17.6 | 15.0 | 2.8 | 2.6 | 16.7 | (14.2) |
| Desay SV | 002920 CH | BUY | 119.57 | 161.00 | 34.6 | 9,434 | 59.7 | 38.2 | 10.7 | 8.7 | 19.3 | (14.3) |
| Nexteer | 1316 HK | BUY | 4.85 | 10.00 | 106.2 | 1,566 | 19.1 | 7.9 | 0.8 | 0.7 | 4.1 | (12.4) |
| Minth Group | 425 HK | BUY | 21.40 | 30.00 | 40.2 | 3,197 | 15.0 | 12.4 | 7.1 | 4.8 | 7.3 | 0.7 |
| Ningbo Xusheng | 603305 CH | BUY | 36.39 | 59.00 | 62.1 | 3,267 | 32.4 | 22.8 | 5.3 | 4.4 | 17.7 | 8.9 |
| CATL | 300750 CH | BUY | 423.80 | 640.00 | 51.0 | 140,948 | 39.9 | 28.4 | 6.7 | 5.5 | 18.7 | (41.9) |
| EVE Energy | 300014 CH | BUY | 92.20 | 137.00 | 48.6 | 25,109 | 59.6 | 30.8 | 6.3 | 5.3 | 11.6 | 15.5 |
| Ganfeng Lithium | 1772 HK | SELL | 65.30 | 52.00 | (20.4) | 16,903 | 4.4 | 6.8 | 2.2 | 1.8 | 66.1 | 0.2 |
| GEM Co., Ltd. | 002340 CH | SELL | 7.79 | 5.10 | (34.5) | 4,793 | 23.3 | 24.7 | 2.4 | 2.2 | 10.7 | 50.2 |
| Guangzhou Tinci | 002709 CH | SELL | 49.01 | 31.00 | (36.7) | 12,035 | 8.7 | 11.6 | 3.9 | 3.1 | 56.1 | 17.8 |
| China Meidong | 1268 HK | BUY | 15.38 | 20.00 | 30.0 | 2,469 | 15.5 | 10.1 | 4.5 | 3.4 | 30.0 | (53.3) |
| Zhongsheng Group | 881 HK | BUY | 39.50 | 65.00 | 64.6 | 11,893 | 10.5 | 8.5 | 2.0 | 1.7 | 21.7 | 4.8 |
| Yadea | 1585 HK | BUY | 13.02 | 18.00 | 38.2 | 5,016 | 18.0 | 14.2 | 6.1 | 4.8 | 38.2 | (185.2) |


Source: Bloomberg, UOB Kay Hian



- According to BYD, this was partly due to the COVID-19 lockdowns, which deterred the deliveries of vehicles to customers, and inventory build-up by dealers. In December, BYD's insurance registrations grew 11% wow and 10% mom to 44,799 units in the second week (5-11 Dec 22) and grew 9% mom to 85,0942 units in the first two weeks (28 Nov-11 Dec 22). Based on the ongoing momentum, BYD's insurance registration and export will probably reach 190,000 units and 15,000-20,000 units in Dec 22, arriving at a combined volume of 205,000-210,000 units in Dec 22, vs the company's Dec 22 wholesale shipment target of 280,000 units. We do not see it as a big problem for BYD, given the 3-6 months in car delivery cycle, over 800,000 units in orders on hand and over 200,000 units in monthly order intakes. Looking ahead, BYD targets to sell at least 3m units in 2023, including 2.7m-2.8m in domestic sales (220,000-230,000/month) and 200,000-300,000 units in exports (16,700-25,000 units/month). We deem this target attainable, based on the ramp-up of the Ocean series models and the debuts of at least 10 new models in 2023. We keep our estimates on BYD's 2022/23/24 sales at 1.8m units/3.0m units/4.0m units respectively.
- Li Auto's insurance registrations in first two weeks of Dec 22 fell short of delivery guidance. Li Auto's insurance registrations plummeted by 28.7% wow and 4.5% mom to 2,982 units in the second week of Dec 22 (5-11 Dec 22) and still grew 34.6% mom to 7,241 units in the first two weeks of Dec 22 (28 Nov-11 Dec 22). This compares with management's guided Dec 22 deliveries of 19,914-22,914 units. Li Auto posted disappointing 3Q22 results with revenue of Rmb9.34b (+20% yoy/+7% qoq) coming in 3% below consensus, and net loss of Rmb1.64b (+7,526% yoy/+165% qoq) exceeding consensus' estimates by 39%. However, during the results conference call, management guided for 45,000-48,000 units in deliveries for 4Q22, 18,000-25,000 units in monthly deliveries in 1Q23 and 300,000 units in deliveries for 2023, based on the ramp-up of L8 and debut of L7. We keep our estimates for 2022-24 deliveries at 130,000 units/240,000 units/350,000 units respectively.
- 2023 forecasts: Automobile sales and ICV sales to drop 3% and 13% respectively; EV sales to grow 30%. We anticipate China's automobile sales to drop 3% yoy to 26.57m units, including 22.91m units of passenger vehicles (PV) (-3% yoy) and 3.66m units of commercial vehicles (CV) (flat yoy), based on the full roll-back of stimulus by end-22. By powertrain, we project sales of internal combustion vehicles (ICV) to drop 13% to 17.87m units, and electric vehicle (EV) sales to grow 30% yoy to 8.69m units, of which 8.235m units will be passenger EVs (+30% yoy) and 457,000 units commercial EVs (+30% yoy). EVs' market share will probably rise from 25% in 2022 to 33% in 2023. Our estimates are more conservative than China Association of Automobile Manufacturers (CAAM) and CPCA. CAAM estimates 2023 China's automobile sales at 27.6m units (+3% yoy), including 23.8m units of PVs (+1.3% yoy) and 3.8m units of CVs (+15% yoy), and China's EV sales at 9m unis (+35% yoy). CPCA estimates 2023 China PV retail sales and wholesale shipment at 20.6m units (flat yoy) and 23.5m units (+1% yoy) respectively, of which 15.1m units will be ICVs (-10% yoy) and 8.4m units passenger EVs (+30% yoy), based on the extension of the halving of vehicle purchase tax rate for ICVs from end-22 to mid-23 or end-23.
- China's EV sales growth driven more by market force now. The subsidies of Rmb4,800/vehicle for plug-in hybrid electric vehicles (PHEV) and Rmb12,800/vehicle for pure battery electric vehicles (BEV) will expire by 31 Dec 22. It is worried that the absence of EV purchase subsidies will dent EV sales in China. We believe that the subsidy expiry will have limited impact on China's EV sales, as subsidies generally account for less than 10% of total EV prices, compared with 30-50% in 2015. China's EV sales are increasingly driven by market force rather than by policies. Although EVs priced above Rmb300,000 have been removed from subsidy list since 2021, their sales surged 270% yoy in 2021 and over 80% in 2022. Meanwhile, OEMs are raising EV prices to partially pass on the subsidy cut to customers. BYD just announced that it would be raising product prices by Rmb2,000-6,000 from 1 Jan 23. Shanghai will cease issuing green licences to PHEVs from 1 Jan 23. We do not see significant impact of the policy on PHEV sales in China as people buy PHEVs for superior fuel efficiency. We expect PHEVs' share of total EV sales in China to rise from 20% in 2022 to 25%/30%/35% in 2023/24/25.

Friday, 16 December 2022

DAILY AVERAGE PV SALES VOLUME GROWTH



Source: CPCA

EV INSURANCE REGISTRATION NUMBER

5-11

| | J-11 | HIOHI | VVOVV | 20 IVUV- | IIIOIII |
|--------------|---------|--------|--------|----------|---------|
| | Dec | % chg | % chg | 11 Dec | % chg |
| BYD | 44,799 | 10.0 | 11.3 | 85,042 | 9.2 |
| Tesla | 12,977 | (6.9) | 11.2 | 24,647 | (1.9) |
| Wuling | 9,479 | 17.6 | 13.8 | 17,811 | 14.2 |
| Changan | 8,448 | 26.5 | 44.4 | 14,299 | 11.5 |
| Aion | n.a. | n.a. | n.a. | 4,876 | (46.3) |
| Geely | 3415 | (11.0) | (8.3) | 7,139 | 5.9 |
| Nio | 2,982 | (4.5) | (5.1) | 6,123 | 2.5 |
| Li Auto | 3,013 | (4.5) | (28.7) | 7,241 | 34.6 |
| Chery | 3,437 | 32.9 | n.a. | 3,437 | (31.0) |
| Aito | 2,618 | (19.8) | 15.4 | 4,887 | (14.8) |
| Zeekr | 2,477 | 34.5 | (19.1) | 5,537 | 33.5 |
| Neta | 2,893 | 34.9 | (68.0) | 11,923 | 195.1 |
| Leapmotor | 2,008 | (6.3) | - | 4,016 | 87.3 |
| XPeng | 2,127 | 92.1 | 8.4 | 4,089 | 84.0 |
| Passenger EV | 140,000 | 16.7 | 8.5 | 269,000 | 16.7 |
| PV | 462,000 | 29.1 | 19.4 | 849,000 | 19.0 |
| | | | | | |

Source: www.cnevpost.com

PE BAND - AUTO SECTOR



Source: Bloomberg, UOB Kay Hian

CHINA AUTO SALES FORECASTS

| Sales volume (m units) | 2021 | 2022F | 2023F |
|------------------------|-------|-------|--------|
| EV | 3.52 | 6.69 | 8.69 |
| Passenger EV | 3.33 | 6.34 | 8.23 |
| Commercial EV | 0.19 | 0.35 | 0.46 |
| ICV | 22.73 | 20.59 | 17.88 |
| Total | 26.25 | 27.28 | 26.57 |
| yoy chg (%) | | | |
| EV | 157.4 | 90.0 | 30.0 |
| Passenger EV | 167.4 | 90.0 | 30.0 |
| Commercial EV | 54.2 | 90.0 | 30.0 |
| ICV | (5.0) | (9.4) | (13.2) |
| Total | 3.8 | 3.9 | (2.6) |

Source: UOB Kay Hian



• Exports emerging as a new growth driver of China's EV industry. China's vehicle export volume spiked by 71% and yoy and 5% mom to a record of 370,000 units in Nov 22, and surged by 54% yoy to 2.99m units in 11M22. China's vehicle export value grew by 65% yoy to US\$52b in 11M22, implying 7% yoy hike in ASP to Rmb17,390/unit in 11M22. Ytd, China has taken over Germany's position as the world's second largest vehicle exporter, closely following the largest vehicle exporter Japan. Since 2021, China's vehicle export growth has been been driven by EVs, whose share in the country's total export volume soared from 21% in 2019-20 to 28% in 2021 and 33% in 10M22. By type, pure electric PVs, plug-in hybrid electric PVs, electric trucks, electric buses and special purpose EVs accounted for 84.5%, 8.5%, 1.6%, 0.6% and 4.8% of China's total EV export volume in 10M22. Exports contributed 16-17% of China's total EV wholesale shipment in 2021-10M22. Asia is the largest overseas market of China's EV exports, but its share in the country's total vehicle export volume shrank from 42% in 2020 to 36% in

10M22. Europe's and North America's share of China's overseas vehicle sales volume

hiked from 16% and 9% in 2020 to 25% and 12% in 10M22.

By company, SAIC's MG exported the most vehicle overseas (11% share), followed by Tesla (9% share). As for EVs, Tesla is the biggest EV exporter in China, contributing 29% of the country's total EV export volume, with Chinese OEMs (SAIC, BYD, etc.) jointly taking up the remaining 71% share. Meanwhile, BYD has been stepping up its export endeavours since 2H22, with monthly export volume spiking from less than 1,000 units in 1H22 to over 12,000 units in Nov 22, driven by models like Atto 3 (Yuan Plus), Han, Tang, Seal and Dolphin. The major overseas markets for BYD are Australia, Japan, India, Thailand, Malaysia, Netherlands, the UK, France, Germany and Brazil. We expect BYD's overseas sales to grow from 50,000 units (3% of total sales) in 2022 to 250,000 units (8% of total sales) in 2023 and 400,000 units (10% of total sales) in 2024. As for China as a whole, we expect exports as a percentage of EV sales to rise from 16-17% currently to above 20% in 2025.

• Geely's premium EV brand Zeekr aiming for IPO in the US market by 2Q23. Zeekr filed an application for an IPO with the US Security and Exchange Commission on 7 Dec 22. Zeekr is valued at US\$10b and the company aims to raise more than US\$1b in proceeds from the IPO. Geely currently holds a 58.2% stake in Zeekr, and the latter will continue to be a non-wholly owned subsidiary of Geely after the completion of the spin-off with an expected maximum applicable spin-off ratio of 5-25%. The listing of Zeekr will hopefully bring in US\$1b new capital to the company, easing the financial pressure of SG&A and R&D.

ACTION


- Maintain UNDERWEIGHT based on the prospective decline in PV sales in 2023 with the expiry of stimulus. We still prefer the EV segment, based on the accelerating electrification of vehicles against the backdrop of sustained high oil prices and the prospective cost reductions from the declines in battery material prices. Within the EV segment, we prefer the parts segment to OEMs, as the former has higher market concentration, and it is supplying to an increasing number of OEM brands. CATL, Fuyao Glass and Ningbo Xusheng remain our top picks. We are adding Desay into our list of top picks, based on the company's leading position in the burgeoning smart cockpit and ADAS markets in China. Our BUY calls are in the following order of preference: CATL, Fuyao Glass, Desay, Ningbo Xusheng, Minth, EVE Energy, Yadea, GWM, GAC, Zhongsheng, Meidong, Nexteer, BYD, Li Auto.
- **Upgrade Li Auto from HOLD to BUY on valuation**, as its share price has fallen well below our target price of HK\$100.00 (10-year DCF based on 19% WACC, 30% 2025-32 FCF growth, 4% terminal growth).

RISKS

• Weaker-than-expected demand after the rollback of stimulus.


Friday, 16 December 2022

VEHICLE EXPORT VOLUME OF JAPAN, CHINA AND GERMANY



Source: Japan Automobile Manufacturers Association (JAMA), CAAM, Verband der Automobilindustrie (VDA)

CHINA VEHICLE EXPORT VOLUME BY TYPE



Source: CAAM



Friday, 16 December 2022

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



Friday, 16 December 2022

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

| ollowing table. | |
|-----------------|--|
| General | This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or |
| | located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to |
| | applicable law or regulation. |
| Hong Kong | This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the |
| | Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has |
| | trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed |
| | corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under |
| | Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong |
| | Kong and contains research analyses or reports from a foreign research house, please note: |
| | (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong |
| | Kong in respect of any matters arising from, or in connection with, the analysis or report; and |
| | (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong |
| | who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the |
| | analyses or reports only to the extent required by law. |
| Indonesia | This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority |
| | of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a |
| | foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant |
| | foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report. |
| Malaysia | Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the |
| | recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, |
| | at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the |
| | registered person under CMSA to distribute any research analyses in Malaysia. |
| Singapore | This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital |
| | markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the |
| | report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: |
| | (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore |
| | in respect of any matters arising from, or in connection with, the analysis or report; and |
| | (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore |
| | who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the |
| | contents of the analyses or reports only to the extent required by law. |
| Thailand | This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated |
| | by the Securities and Exchange Commission of Thailand. |
| United | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning |
| Kingdom | of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in |
| | the UK is intended only for institutional clients. |
| United | This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. |
| States of | laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its |
| America | contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in |
| ('U.S.') | the report should contact UOB Kay Hian (US) Inc. directly. |

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W